This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Trebananib
DrugBank Accession Number
DB12056
Background

Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Trebananib
External IDs
  • Amg 386

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Alendronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Alendronic acid.
Clodronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Clodronic acid.
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trebananib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trebananib.
Etidronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Etidronic acid.
IbandronateThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Ibandronate.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trebananib.
Pamidronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Pamidronic acid.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Trebananib.
Risedronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Risedronic acid.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
X8Y5U6NC7E
CAS number
894356-79-7

References

General References
Not Available
PubChem Substance
347911276

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentFallopian Tubes Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
3TerminatedTreatmentFallopian Tubes Cancer / Malignant Peritoneal Neoplasm / Ovarian Cancer1
3TerminatedTreatmentFallopian Tubes Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
2Active Not RecruitingTreatmentGiant Cell Glioblastoma / Glioblastoma Multiforme (GBM) / Gliosarcoma / Oligodendrogliomas / Recurrent Brain Neoplasm / Recurrent Glioblastoma1
2CompletedTreatmentAdult Angiosarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentAdvanced Hepatocellular Carcinoma (HCC) / Inoperable Hepatocellular Carcinoma1
2CompletedTreatmentAdvanced Renal Cell Carcinoma (aRCC)2
2CompletedTreatmentAdvanced Renal Cell Carcinoma (aRCC) / Advanced Sarcomatoid Renal Cell Carcinoma / Stage III Renal Cell Cancer AJCC v7 / Stage IV Renal Cell Cancer AJCC V71
2CompletedTreatmentCarcinoma / Colorectal Cancer / Gastrointestinal Cancers / Malignancies / Malignant Neoplasm of Colon / Metastases / Metastatic Cancers / Metastatic Colorectal Cancer (CRC) / Oncology / Rectal Carcinoma1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Endometrioid Stromal Sarcoma / Recurrent Uterine Corpus Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 20, 2016 21:16 / Updated at February 21, 2021 18:53